UA80711C2 - Topical treatment of skin diseases - Google Patents

Topical treatment of skin diseases Download PDF

Info

Publication number: UA80711C2
Authority: UA; Ukraine
Prior art keywords: mono; alkyl; aryl; polyunsaturated; members
Prior art date: 2002-07-11

Application number

UAA200500163A

Other languages

English (en)

Ukrainian (uk)

Inventor

Chris Rundfeldt

Hildegard Kuss

Norbert Hoefgen

Original Assignee

Elbion Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-11

Filing date

2003-10-07

Publication date

2007-10-25

2003-10-07 Application filed by Elbion Ag filed Critical Elbion Ag

2007-10-25 Publication of UA80711C2 publication Critical patent/UA80711C2/uk

Links

238000011282 treatment Methods 0.000 title claims abstract description 27
208000017520 skin disease Diseases 0.000 title claims abstract description 16
230000000699 topical effect Effects 0.000 title description 5
238000000034 method Methods 0.000 claims abstract description 29
208000010668 atopic eczema Diseases 0.000 claims abstract description 19
230000000172 allergic effect Effects 0.000 claims abstract description 13
230000002757 inflammatory effect Effects 0.000 claims abstract description 10
150000001875 compounds Chemical class 0.000 claims description 32
229920006395 saturated elastomer Polymers 0.000 claims description 29
125000000623 heterocyclic group Chemical group 0.000 claims description 28
125000004429 atom Chemical group 0.000 claims description 18
125000005842 heteroatom Chemical group 0.000 claims description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
201000010099 disease Diseases 0.000 claims description 9
201000008937 atopic dermatitis Diseases 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 7
125000002837 carbocyclic group Chemical group 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
125000005843 halogen group Chemical group 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
125000001424 substituent group Chemical group 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 5
206010012434 Dermatitis allergic Diseases 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
125000002950 monocyclic group Chemical group 0.000 claims description 4
239000008177 pharmaceutical agent Substances 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
125000004434 sulfur atom Chemical group 0.000 claims description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 2
208000026935 allergic disease Diseases 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
239000003246 corticosteroid Substances 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
239000001301 oxygen Substances 0.000 claims description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
JHFAEUICJHBVHB-UHFFFAOYSA-N 1h-indol-2-ol Chemical class C1=CC=C2NC(O)=CC2=C1 JHFAEUICJHBVHB-UHFFFAOYSA-N 0.000 abstract description 3
241000699670 Mus sp. Species 0.000 description 34
210000003491 skin Anatomy 0.000 description 33
CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical group COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 30
229950001653 cilomilast Drugs 0.000 description 24
206010014025 Ear swelling Diseases 0.000 description 18
241001465754 Metazoa Species 0.000 description 18
210000005069 ears Anatomy 0.000 description 18
230000000694 effects Effects 0.000 description 17
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
230000004054 inflammatory process Effects 0.000 description 15
239000003112 inhibitor Substances 0.000 description 15
230000008961 swelling Effects 0.000 description 14
102000004127 Cytokines Human genes 0.000 description 13
108090000695 Cytokines Proteins 0.000 description 13
206010061218 Inflammation Diseases 0.000 description 13
206010070834 Sensitisation Diseases 0.000 description 13
210000004027 cell Anatomy 0.000 description 13
230000008313 sensitization Effects 0.000 description 13
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 12
238000002474 experimental method Methods 0.000 description 11
102000016951 Chemokine CXCL2 Human genes 0.000 description 10
108010014414 Chemokine CXCL2 Proteins 0.000 description 10
-1 1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl Chemical group 0.000 description 9
230000002401 inhibitory effect Effects 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
201000004624 Dermatitis Diseases 0.000 description 7
230000007774 longterm Effects 0.000 description 7
238000012360 testing method Methods 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
230000004941 influx Effects 0.000 description 6
239000000203 mixture Substances 0.000 description 6
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 5
206010020751 Hypersensitivity Diseases 0.000 description 5
239000006071 cream Substances 0.000 description 5
210000003979 eosinophil Anatomy 0.000 description 5
210000004969 inflammatory cell Anatomy 0.000 description 5
230000035515 penetration Effects 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
206010012438 Dermatitis atopic Diseases 0.000 description 4
102000015696 Interleukins Human genes 0.000 description 4
108010063738 Interleukins Proteins 0.000 description 4
108010044467 Isoenzymes Proteins 0.000 description 4
239000013566 allergen Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
239000000499 gel Substances 0.000 description 4
210000003714 granulocyte Anatomy 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
210000000440 neutrophil Anatomy 0.000 description 4
239000002674 ointment Substances 0.000 description 4
230000002062 proliferating effect Effects 0.000 description 4
241000282412 Homo Species 0.000 description 3
206010020649 Hyperkeratosis Diseases 0.000 description 3
208000001126 Keratosis Diseases 0.000 description 3
201000011152 Pemphigus Diseases 0.000 description 3
210000001015 abdomen Anatomy 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000010562 histological examination Methods 0.000 description 3
229940047122 interleukins Drugs 0.000 description 3
210000002510 keratinocyte Anatomy 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000006210 lotion Substances 0.000 description 3
201000001976 pemphigus vulgaris Diseases 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
210000004927 skin cell Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
NLMQHXUGJIAKTH-UHFFFAOYSA-N 4-hydroxyindole Chemical class OC1=CC=CC2=C1C=CN2 NLMQHXUGJIAKTH-UHFFFAOYSA-N 0.000 description 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
101800000414 Corticotropin Proteins 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
240000001307 Myosotis scorpioides Species 0.000 description 2
102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
206010039705 Scleritis Diseases 0.000 description 2
206010039710 Scleroderma Diseases 0.000 description 2
206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
206010044223 Toxic epidermal necrolysis Diseases 0.000 description 2
231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000002390 adhesive tape Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
208000030961 allergic reaction Diseases 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
208000010247 contact dermatitis Diseases 0.000 description 2
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
229960000258 corticotropin Drugs 0.000 description 2
210000004207 dermis Anatomy 0.000 description 2
210000002615 epidermis Anatomy 0.000 description 2
YOMFVLRTMZWACQ-UHFFFAOYSA-N ethyltrimethylammonium Chemical compound CC[N+](C)(C)C YOMFVLRTMZWACQ-UHFFFAOYSA-N 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000006870 function Effects 0.000 description 2
244000144993 groups of animals Species 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
206010021198 ichthyosis Diseases 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000006872 improvement Effects 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
229940028885 interleukin-4 Drugs 0.000 description 2
230000037041 intracellular level Effects 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012907 medicinal substance Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000013641 positive control Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
235000002020 sage Nutrition 0.000 description 2
238000002317 scanning near-field acoustic microscopy Methods 0.000 description 2
231100000444 skin lesion Toxicity 0.000 description 2
206010040882 skin lesion Diseases 0.000 description 2
239000007921 spray Substances 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
125000006508 2,6-difluorobenzyl group Chemical class [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 description 1
125000004176 4-fluorobenzyl group Chemical class [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
NGHVIOIJCVXTGV-ALEPSDHESA-N 6-aminopenicillanic acid Chemical compound [O-]C(=O)[C@H]1C(C)(C)S[C@@H]2[C@H]([NH3+])C(=O)N21 NGHVIOIJCVXTGV-ALEPSDHESA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
206010063409 Acarodermatitis Diseases 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
208000023095 Autosomal dominant epidermolytic ichthyosis Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
206010006487 Bronchostenosis Diseases 0.000 description 1
101100153505 Caenorhabditis elegans tni-1 gene Proteins 0.000 description 1
ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
206010011668 Cutaneous leishmaniasis Diseases 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
208000007163 Dermatomycoses Diseases 0.000 description 1
201000009040 Epidermolytic Hyperkeratosis Diseases 0.000 description 1
206010062488 Erythema migrans Diseases 0.000 description 1
108010008165 Etanercept Proteins 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
208000001913 Lamellar ichthyosis Diseases 0.000 description 1
208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
208000000592 Nasal Polyps Diseases 0.000 description 1
206010029379 Neutrophilia Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
208000006311 Pyoderma Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
241000447727 Scabies Species 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
101100046504 Symbiobacterium thermophilum (strain T / IAM 14863) tnaA2 gene Proteins 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
206010000496 acne Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003470 adrenal cortex hormone Substances 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
230000008369 airway response Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
229960002459 alefacept Drugs 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
229960003556 aminophylline Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
208000024998 atopic conjunctivitis Diseases 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
201000000751 autosomal recessive congenital ichthyosis Diseases 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
208000000594 bullous pemphigoid Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000009134 cell regulation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229960001803 cetirizine Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
239000004927 clay Substances 0.000 description 1
210000002777 columnar cell Anatomy 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
229960002806 daclizumab Drugs 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000035617 depilation Effects 0.000 description 1
230000002951 depilatory effect Effects 0.000 description 1
201000003929 dermatomycosis Diseases 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
229960000520 diphenhydramine Drugs 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960002311 dithranol Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
229960002179 ephedrine Drugs 0.000 description 1
208000007150 epidermolysis bullosa simplex Diseases 0.000 description 1
208000033286 epidermolytic ichthyosis Diseases 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
229960000403 etanercept Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
208000014617 hemorrhoid Diseases 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
229960000930 hydroxyzine Drugs 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
238000005286 illumination Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
229960001317 isoprenaline Drugs 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
201000011486 lichen planus Diseases 0.000 description 1
239000000865 liniment Substances 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
229960003088 loratadine Drugs 0.000 description 1
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
230000004199 lung function Effects 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
238000011418 maintenance treatment Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
108091028838 miR-2 stem-loop Proteins 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000000897 modulatory effect Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000009520 phase I clinical trial Methods 0.000 description 1
KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
229960005330 pimecrolimus Drugs 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
238000005070 sampling Methods 0.000 description 1
208000005687 scabies Diseases 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
230000009476 short term action Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
231100000430 skin reaction Toxicity 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

UAA200500163A 2002-07-11 2003-10-07 Topical treatment of skin diseases UA80711C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US39522102P	2002-07-11	2002-07-11
PCT/EP2003/007514 WO2004006920A1 (en)	2002-07-11	2003-07-10	Topical treatment of skin diseases

Publications (1)

Publication Number	Publication Date
UA80711C2 true UA80711C2 (en)	2007-10-25

Family

ID=30115840

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200500163A UA80711C2 (en)	2002-07-11	2003-10-07	Topical treatment of skin diseases

Country Status (20)

Country	Link
US (1)	US20040038958A1 (pl)
EP (1)	EP1531818A1 (pl)
JP (1)	JP2005537262A (pl)
KR (1)	KR20050021464A (pl)
CN (1)	CN1681500A (pl)
AR (1)	AR040647A1 (pl)
AU (1)	AU2003254332B2 (pl)
BR (1)	BR0312696A (pl)
CA (1)	CA2492093A1 (pl)
HR (1)	HRP20050133A2 (pl)
IL (1)	IL166016A0 (pl)
MX (1)	MXPA05000486A (pl)
NO (1)	NO20050718L (pl)
NZ (1)	NZ537482A (pl)
PL (1)	PL375487A1 (pl)
RU (1)	RU2005103608A (pl)
TW (1)	TW200410690A (pl)
UA (1)	UA80711C2 (pl)
WO (1)	WO2004006920A1 (pl)
ZA (1)	ZA200500108B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1546142A4 (en)	2002-08-29	2007-10-17	Merck & Co Inc	INDOLES HAVING ANTIDIABETIC EFFECT
CN100457730C (zh)	2002-08-29	2009-02-04	默克公司	具有抗糖尿病活性的吲哚化合物
WO2004107678A2 (en) *	2003-05-28	2004-12-09	Artimi Ltd	Ultra-wideband network, device, device controller, method and data packet for establishing a mesh network and forwarding packets on another channel
EP1713471B1 (en) *	2004-02-06	2012-01-18	MEDA Pharma GmbH & Co. KG	Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
ES2413011T3 (es) *	2004-02-06	2013-07-15	Meda Pharma Gmbh & Co. Kg	Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
JP4961131B2 (ja) *	2004-10-29	2012-06-27	田辺三菱製薬株式会社	皮膚損傷治療剤
TWI339578B (en) *	2004-10-29	2011-04-01	Mitsubishi Tanabe Pharma Corp	Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions
EP1863476B1 (en) *	2005-03-16	2016-02-03	MEDA Pharma GmbH & Co. KG	The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
NZ591969A (en) *	2005-12-21	2012-05-25	Meda Pharma Gmbh & Co Kg	Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
US7645752B2 (en) *	2006-01-13	2010-01-12	Wyeth Llc	Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
AU2007218725B2 (en)	2006-02-21	2011-12-01	Eisai R & D Management Co., Ltd.	4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
US8530654B2 (en)	2007-02-16	2013-09-10	Eisai R&D Management Co., Ltd.	Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid
AU2008290000B2 (en)	2007-08-17	2012-05-10	Eisai R & D Management Co., Ltd.	Method for producing quinazoline derivative
CA2696793A1 (en)	2007-08-17	2009-02-26	Eisai R&D Management Co., Ltd.	Novel preparation for external use
JOP20130213B1 (ar)	2012-07-17	2021-08-17	Takeda Pharmaceuticals Co	معارضات لمستقبلht3-5
CA2962429C (en)	2014-09-29	2023-01-03	Takeda Pharmaceutical Company Limited	Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide
CA3010615C (en)	2016-01-14	2024-02-20	Beth Israel Deaconess Medical Center, Inc.	Mast-cell modulators and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4341783A (en) *	1980-07-31	1982-07-27	Lemmon Company	Topical use of dyphylline and dyphylline containing compositions
AU6821294A (en) *	1993-04-30	1994-11-21	Rodner R. Winget	Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto
PL198983B1 (pl) *	1998-04-28	2008-08-29	Elbion Ag	Nowe hydroksyindole, ich zastosowanie jako inhibitorów fosfodiesterazy 4 oraz sposoby ich wytwarzania

2003
- 2003-07-01 US US10/611,649 patent/US20040038958A1/en not_active Abandoned
- 2003-07-09 TW TW092118759A patent/TW200410690A/zh unknown
- 2003-07-10 BR BR0312696-0A patent/BR0312696A/pt not_active IP Right Cessation
- 2003-07-10 PL PL03375487A patent/PL375487A1/pl unknown
- 2003-07-10 AU AU2003254332A patent/AU2003254332B2/en not_active Ceased
- 2003-07-10 MX MXPA05000486A patent/MXPA05000486A/es active IP Right Grant
- 2003-07-10 EP EP03763810A patent/EP1531818A1/en not_active Withdrawn
- 2003-07-10 KR KR10-2005-7000572A patent/KR20050021464A/ko not_active Withdrawn
- 2003-07-10 AR AR20030102493A patent/AR040647A1/es not_active Application Discontinuation
- 2003-07-10 NZ NZ537482A patent/NZ537482A/en unknown
- 2003-07-10 CN CNA038215209A patent/CN1681500A/zh active Pending
- 2003-07-10 CA CA002492093A patent/CA2492093A1/en not_active Abandoned
- 2003-07-10 WO PCT/EP2003/007514 patent/WO2004006920A1/en not_active Ceased
- 2003-07-10 RU RU2005103608/04A patent/RU2005103608A/ru not_active Application Discontinuation
- 2003-07-10 JP JP2004520586A patent/JP2005537262A/ja not_active Withdrawn
- 2003-07-10 HR HR20050133A patent/HRP20050133A2/hr not_active Application Discontinuation
- 2003-10-07 UA UAA200500163A patent/UA80711C2/uk unknown
2004
- 2004-12-28 IL IL16601604A patent/IL166016A0/xx unknown
2005
- 2005-01-06 ZA ZA200500108A patent/ZA200500108B/en unknown
- 2005-02-10 NO NO20050718A patent/NO20050718L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2003254332B2 (en)	2009-01-08
CA2492093A1 (en)	2004-01-22
CN1681500A (zh)	2005-10-12
AR040647A1 (es)	2005-04-13
MXPA05000486A (es)	2005-07-22
NZ537482A (en)	2006-09-29
TW200410690A (en)	2004-07-01
ZA200500108B (en)	2005-02-23
BR0312696A (pt)	2005-04-26
NO20050718L (no)	2005-04-01
RU2005103608A (ru)	2005-06-27
PL375487A1 (pl)	2005-11-28
US20040038958A1 (en)	2004-02-26
EP1531818A1 (en)	2005-05-25
KR20050021464A (ko)	2005-03-07
IL166016A0 (en)	2006-01-15
HRP20050133A2 (en)	2005-04-30
JP2005537262A (ja)	2005-12-08
WO2004006920A1 (en)	2004-01-22
AU2003254332A1 (en)	2004-02-02

Publication	Publication Date	Title
UA80711C2 (en)	2007-10-25	Topical treatment of skin diseases
Chen et al.	2018	Activating AMPK to restore tight junction assembly in intestinal epithelium and to attenuate experimental colitis by metformin
Matsubara et al.	2006	Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness
JP2014510064A (ja)	2014-04-24	Ｎｒｆ２活性剤としてのカルコン誘導体
Mokry et al.	2017	Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs
CZ6498A3 (cs)	1998-06-17	Použití rapamycinu a jeho derivátů v kombinaci s antagonistou NMDA a/nebo AMPA pro výrobu farmaceutických prostředků
Fujii et al.	2017	Effect of a retinoid X receptor partial agonist on airway inflammation and hyperresponsiveness in a murine model of asthma
Xu et al.	2020	Astilbin combined with lipopolysaccharide induces IL-10-producing regulatory B cells via the STAT3 signalling pathway
Chiariotti et al.	2015	Epigenetic alterations induced by bacterial lipopolysaccharides
Tanaka et al.	2012	Suppression of interleukin 17 production by Brazilian propolis in mice with collagen-induced arthritis
Cho et al.	2010	Licochalcone E reduces chronic allergic contact dermatitis and inhibits IL-12p40 production through down-regulation of NF-κB
JP2012152127A (ja)	2012-08-16	皮膚バリア機能回復剤
EP1277743A1 (en)	2003-01-22	Oxa(thia)zolidine derivative and anti-inflammatory drug
US20050136444A1 (en)	2005-06-23	Treating neuropathic pain with neuropeptide FF receptor 2 agonists
JP2015534942A (ja)	2015-12-07	Ｃｂｐ／カテニン阻害剤を用いる過剰増殖性及び前がん性皮膚病の治療
EP1101496A1 (en)	2001-05-23	Therapeutic agents for allergic diseases
EP2301539A1 (de)	2011-03-30	PPAR-gamma-Agonisten zur Behandlung von Erkrankungen mit pathophysiologischer Beteiligung von TH17-Lymphozyten
Di Gioia et al.	2023	Host-derived oxidized phospholipids initiate effector-triggered immunity fostering lethality upon microbial encounter
Xu et al.	2019	A scalable total synthesis of Halofuginone
KR102665487B1 (ko)	2024-05-10	염증 질환의 예방 및 치료
CN114599356A (zh)	2022-06-07	自身炎症性病症的治疗
Fang et al.	2025	Topical TYK2 inhibitor ameliorates psoriasis‐like dermatitis via the AKT‐SP1‐NGFR‐AP1 pathway in keratinocytes
US20240269138A1 (en)	2024-08-15	Mmp13 as a therapeutic target for allergic inflammatory diseases
WO2024211656A1 (en)	2024-10-10	Pyrvinium and its derivatives for the treatment of pre-cancers
JP2026513889A (ja)	2026-05-01	前がんの治療のためのピルビニウムおよびその誘導体